The Empaveli Resubmission Journey: From FDA CRL to Approval
Hello Regulatory Scientists, Today, let’s explore the journey of Empaveli (pegcetacoplan) from receiving an FDA Complete Response Letter (CRL) to achieving approval. This case study provides valuable insights and lessons that can guide companies developing new drugs today. Regulatory History and Initial Submission Drug: Empaveli (pegcetacoplan) Mechanism of Action: Complement inhibitor that binds to complement protein […]
The Viltepso Resubmission Journey: From FDA CRL to Approval
Hello Regulatory Scientists, Today, let’s explore the journey of Viltepso (viltolarsen) from receiving an FDA Complete Response Letter (CRL) to achieving approval. This case study provides valuable insights and lessons that can guide companies developing new drugs today. Regulatory History and Initial Submission Drug: Viltepso (viltolarsen) Mechanism of Action: Antisense oligonucleotide that binds to exon 53 […]
The Zolgensma Resubmission Journey: From FDA CRL to Approval
Hello Regulatory Scientists, Today, let’s delve into the journey of Zolgensma (onasemnogene abeparvovec) from receiving an FDA Complete Response Letter (CRL) to achieving approval. This case study provides valuable insights and lessons that can guide companies developing new drugs today. Regulatory History and Initial Submission Drug: Zolgensma (onasemnogene abeparvovec) Mechanism of Action: Gene therapy that delivers […]
The Balversa Resubmission Journey: From FDA CRL to Approval
Hello Regulatory Scientists, Today, let’s dive into the journey of Balversa (erdafitinib) from receiving an FDA Complete Response Letter (CRL) to achieving approval. This case study provides valuable insights and lessons that can guide companies developing new drugs today. Regulatory History and Initial Submission Drug: Balversa (erdafitinib) Mechanism of Action: FGFR (fibroblast growth factor receptor) inhibitor, […]